Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2004, for Colgate-Palmolive Company. The company operates globally in two primary segments: Oral, Personal and Home Care, and Pet Nutrition. The reporting period includes the impact of the acquisition of GABA Holding AG, a European oral care company, completed in June 2004.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2004 | Nine Months Ended Sep 30, 2004 |
|---|---|---|
| Net Sales | $2,695.7 million | $7,780.9 million |
| Gross Profit | $1,476.7 million | $4,299.9 million |
| Operating Profit | $537.7 million | $1,653.8 million |
| Net Income | $329.0 million | $1,041.4 million |
| Diluted EPS | $0.58 | $1.83 |
| Cash from Operations (9mo) | $1,230.5 million | |
| Cash and Equivalents (Sep 30, 2004) | $370.6 million | |
| Total Debt (Current + Long-term) | $3,684.7 million |
Margins (Three Months Ended Sep 30, 2004): Gross margin was 54.8%; Operating margin was 19.9%.
Material Changes vs. Prior Period
- Revenue Growth: Worldwide sales increased 7.0% in Q3 2004 and 6.0% for the nine-month period compared to 2003. Growth was driven by unit volume gains (7.0% in Q3) and the GABA acquisition, partially offset by lower net selling prices due to increased promotional spending.
- Profitability: Net income for Q3 2004 declined 10% to $329.0 million from $365.4 million in Q3 2003. For the nine-month period, net income decreased slightly by 1% to $1,041.4 million. Operating profit remained relatively flat in Q3 ($537.7M vs $535.3M) but increased 3% for the nine-month period.
- Cost Pressures: Gross profit margins declined in Q3 due to higher raw material costs and increased commercial investment (advertising and promotions) which outweighed cost reduction savings.
- Tax Rate: The effective tax rate increased to 35.2% in Q3 2004 from 27.6% in Q3 2003, driven by changes in the mix of income across foreign jurisdictions.
Outlook, Risks, and Unusual Items
- Acquisitions: The company acquired GABA Holding AG for approximately $844 million (net cost $729 million) to strengthen its European oral care business. It also acquired a fabric conditioner business in Australia/New Zealand for $34 million.
- Restructuring: The company is implementing workforce reductions and manufacturing realignments in Europe, Latin America, and Asia/Africa. Total expected costs are approximately $70 million, with $59.3 million incurred in 2003. One-time business realignment costs of $12 million were incurred in the first nine months of 2004.
- Share Repurchases: In October 2004, the Board authorized a new program to repurchase up to 20 million shares through December 31, 2005. The company expects to fund this via cash flow and reduce incremental debt from the GABA acquisition by year-end 2005.
- Legal Contingencies: Significant ongoing legal matters include:
- IRS Audit: A challenge to tax deductions for expatriate executives (1996-1998) involving $44 million in tax, with potential subsequent period exposure up to $75 million.
- Brazilian Proceedings: Administrative and civil actions regarding the 1995 Kolynos acquisition, including a suspended fine of approximately $90 million and potential tax assessments of $70 million. Management intends to defend these vigorously.
- Guidance: The filing does not provide specific numerical guidance for the full year 2004 beyond the estimated effective tax rate of 33.4%.
Investor Verification Checklist
- Verify the final purchase price allocation for the GABA acquisition and its impact on goodwill and intangible assets.
- Monitor the resolution of the Brazilian Central Bank fine ($90M) and tax assessments ($70M) related to the Kolynos acquisition.
- Track the progress of the IRS administrative appeal regarding expatriate executive compensation deductions.
- Assess the sustainability of volume growth given the offsetting impact of lower net selling prices and rising raw material costs.
- Review the execution of the new $20 million share repurchase program authorized in October 2004.